There are two arguments against no increase in CD8+ T-cells by using leronlimab. Chronic or high level inflammation causes a drop in CD8+ T-cells due to exhaustion and lowering the inflammation significantly causes a rebound. Blocking CCR5 with leronlimab and therefore RANTES (CCL5) would reduce the TGF-B killing of CD8+ T-cells by TREGS.